Fixed-dose combination liver disorder therapeutic - Waterstone Pharmaceuticals
Latest Information Update: 05 Nov 2014
At a glance
- Originator Waterstone Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver disorders
Most Recent Events
- 05 Nov 2014 Phase-I clinical trials in Liver disorders in China (unspecified route)